.AstraZeneca has used expert system to design a special biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), expecting to separate the antibody-drug conjugate (ADC) coming
Read moreAZ licenses thrown away uncommon illness drug to Monopar Therapies
.Monopar Therapies is actually bouncing back a medicine coming from the scrap heap of AstraZeneca’s unusual disease pipeline. It has certified ALXN-1840, a candidate for
Read moreAN 2 one-halfs headcount, quits phase 3 trial after data disappoint
.AN2 Therapies is actually reassessing its service in reaction to dull midphase records, promising to lay off half its own staff members and also stop
Read moreALX’s fizzling CD47 reaction price sends supply spiraling down
.ALX Oncology’s period 2 gastric cancer cells reaction price has compromised. After viewing its CD47 blocker easily hammered control over the first half of the
Read moreAC Immune views ‘spots’ prospective in Alzheimer’s medication records
.After greater than twenty years of work on neurodegenerative health conditions, Swiss biotech AC Immune cases it could possibly have a video game changer on
Read more